Synapse - Find an Expert

115370 Results

EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis

Meeting Abstract

Vanderbilt, C. M.; Nanda, S.; Singi, S.; Gupta, R.; Goldgof, G.; Ardon, O.; Elkrief, A.; Fuchs, T.; Campanella, G.; Hameed, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

Meeting Abstract

Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma

Meeting Abstract

Guardamagna, M.; Marqueste, C. G.; Malissen, N.; Roy, S.; da Silva, I. P.; Long, G. V.; Smithy, J. W.; Postow, M. A.; Dimitriou, F.; Dummer, R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200

Meeting Abstract

Lebbe, C.; Nghiem, P.; Bhatia, S.; Mortier, L.; Brohl, A. S.; Jacob, N.; Tyroller, K.; Hoffman, J.; D'Angelo, S. P.
Annals of Oncology (2024)

Fulltext@MSK | Save

Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors

Meeting Abstract

Cohen, J. V.; Garyantes, T. K.; Muller, C.; Natale, C. A.; Orloff, M.; Patel, S.; Rodon, J.; Shoushtari, A. N.
Annals of Oncology (2024)

Fulltext@MSK | Save

Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)

Meeting Abstract

Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma

Meeting Abstract

Burton, E.; Wani, K.; Milton, D.; Lazcano, R.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Patel, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

Meeting Abstract

Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)